INCY Stock and Options Trade Setup — Incyte Corporation
Nasdaq · Oncology & Inflammation Biopharma · Moderate-high options liquidity · Large cap · ~$14B
Incyte generates exceptional cash flow from Jakafi — a mature, growing franchise with patent protection extending through 2028 and significant royalty income from Novartis' baricitinib (Olumiant). The pipeline diversification thesis is gradually de-risking the Jakafi cliff concern: axatilimab (GVHD), itacitinib (oncology), and pemigatinib (biliary tract cancer) represent a maturing portfolio with multiple data readouts through 2026-27. The company has amassed substantial cash reserves — over $4B — with minimal debt, providing both acquisition optionality and downside protection. Incyte's discounted valuation relative to its cash-backed fundamentals implies that investors are pricing in material pipeline failure that has not materialized. Options plays around FDA decisions and clinical data readouts offer a structured catalyst-driven strategy.
Score History & Signal Changelog
Preview dataThis page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.
Signal Breakdown
Today's Trade Card
Options Profile
Risks & Fundamentals
Every setup carries risk. Here's what could move INCY against you, plus the key stats that frame any position.
- 1.Jakafi faces biosimilar competition after 2028 patent expiry
- 2.Pipeline failures are high-probability for individual programs — diversification required
- 3.Larger pharma players can outbid for the same M&A targets Incyte pursues
INCY Options Setup — Frequently Asked Questions
Is INCY a good options trade today?+
Incyte Corporation (INCY) currently has an Amora Edge Score of 68/100, ranking it top 40%. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.
What is INCY's win rate on Stoptions.ai setups?+
INCY's historical win rate on closed Stoptions setups is 64%. Win rate is calculated as the percentage of past INCY trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.
What strike and expiry does Stoptions.ai suggest for INCY?+
The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.
How often is the INCY setup updated?+
Every 72 hours we refresh INCY's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If INCY drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.
What does the Amora Edge Score measure for INCY?+
The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to INCY: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is INCY outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. INCY currently scores 68.
How does INCY compare to other Oncology & Inflammation Biopharma setups?+
INCY's sector rank and percentile against other Oncology & Inflammation Biopharma tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Oncology & Inflammation Biopharma Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.
Educational content only — not personalized investment advice. Options carry substantial risk.
Get a Friday recap including setups like INCY.
Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.
No spam. One email Friday afternoon. Unsubscribe in one click.